clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2020-98-9-10-645-649clinmed-137Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСочетание гастроэзофагеальной рефлюксной болезни и синдрома раздраженного кишечника: какие вопросы остаются нерешенными?Gastroesophageal refl ux disease and irritable bowel syndrome overlapping: unresolved issuesШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович — д-р мед. наук., профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии ИКМ им. Н.В. Склифосовского

119991, Москва

Arkady A. Sheptulin — MD, PhD, DSc, Professor Departament of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Medical faculty

119991, Moscow

arkalshep@gmail.comВиноградскаяК. Э.VinogradskayaK. E.

119991, Москва

119991, Moscow

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияFirst Moscow State Medical University named after Sechenov I.M. (Sechenov University)Russian Federation202025032021989-10645649Copyright © Шептулин А.А., Виноградская К.Э., 20212021Шептулин А.А., Виноградская К.Э.Sheptulin A.A., Vinogradskaya K.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/137

В обзоре представлены данные литературы, касающиеся частоты и клинических особенностей сочетания гастро-эзофагеальной рефлюксной болезни (ГЭРБ) и синдрома раздраженного кишечника (СРК). Средняя частота сочетания ГЭРБ и СРК составляет 36–48,8%, но в отдельно взятых работах колеблется от 8–11% до 71–79%. Широкий размах колебаний частоты сочетания объясняется разными подходами к постановке диагнозов ГЭРБ и СРК в различных исследованиях (использование опросников, эндоскопические исследования. рН-импедансометрия пищевода). Высокая частота сочетания ГЭРБ и СРК обусловлена общностью патогенетических факторов обоих заболеваний (нарушения моторики желудочно-кишечного тракта, висцеральная гиперчувствительность). Особенности клинической картины и лечения в случаях сочетания ГЭРБ и СРК изучены недостаточно и требуют дальнейших исследований.

The review presents literature data concerning the rate and clinical features in cases of the gastroesоphageal refl ux disease (GERD) and irritable bowel syndrome (IBS )overlapping. The mean rate of GERD and IBS overlapping is 36–48 .8%, but in individual articles varies from 8–11% to 71–79%. A signifi cant variation in the rate is explained by diff erent approaches to the diagnosis of GERD and IBS in various studies (use of questionnaires, endoscopic examination, esophageal pH-impedancemetry). The high rate of GERD and IBS overlapping is related to the common pathogenetic mechanisms of both diseases (disorders оf gastrointestinal motility, visceral hypersensitivity). The features of the clinical picture and treatment in cases of GERD and IBS overlapping are studied insuffi ciently and require further research.

гастроэзофагеальная рефлюксная болезньсиндром раздраженного кишечникасочетаниеgastroesophageal refl ux diseaseirritable bowel syndromeoverlappingReferencesИвашкин В.Т., Маев И.В., Трухманов А.С., Баранская Е.К., Дронова О.Б., Зайратьянц О.В., Сайфутдинов Р.Г., Шеп ту лин А.А., Лапина Т.Л., Пирогов С.С., Кучерявый Ю.А., Сторонова О.А., Андреев Д.Н. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):75–95.Ivashkin V.T., Mayev I.V., Trukhmanov A.S., Baranskaya Ye.K. , Dronova О.B., Zayratyants О.V., Sayfutdinov R.G., Sheptulin A.A., Lapina T.L., Pirogov S.S., Kucheryavy Yu.A., Storonova O.A., Andreyev D.N. Diagnostics and treatment of gastroesophageal refl ux disease: clinical guidelines of the Russian gastroenterological association. Rossiskii. Zhurnal. Gastroenterologii., Gepatoljgii, Koloproctologii. 2017;27(4):75–95. (in Russian). DOI: 10.22416/1382-4376-2017-27-4-75-95Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller M. Bowel Disorders. Gastroenterology. 2016;150:1393–1407. DOI: 10.1053/j.gastro.2016.02.031Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller M. Bowel Disorders. Gastroenterology. 2016;150:1393–1407. DOI: 10.1053/j.gastro.2016.02.031Nastaskin I., Mehdikhani E., Conklin J., Park S., Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig. Dis. Sci. 2006;51(12):2113–2120. DOI: 10.1007/s10620-006-9306-yNastaskin I., Mehdikhani E., Conklin J., Park S., Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig. Dis. Sci. 2006;51(12):2113–2120. DOI: 10.1007/s10620-006-9306-yLovell R.M., Ford A.C. Prevalence of gastro-esophageal refl ux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am. J. Gastroenterol. 2012;107(12):1793–1801. DOI: 10.1038/ajg.2012.336Lovell R.M., Ford A.C. Prevalence of gastro-esophageal refl ux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am. J. Gastroenterol. 2012;107(12):1793–1801. DOI: 10.1038/ajg.2012.336De Bortoli N., Martinucci I., Bellini M., Savarino E., Savarino V., Blandizzi C., Marchi S. Overlap of functional heartburn and gastroesophageal refl ux disease with irritable bowel syndrome. World J. Gastroenterol. 2013;19(35):5787–5797. DOI: 10.3748/wjg.v19.i35.5787De Bortoli N., Martinucci I., Bellini M., Savarino E., Savarino V., Blandizzi C., Marchi S. Overlap of functional heartburn and gastroesophageal refl ux disease with irritable bowel syndrome. World J. Gastroenterol. 2013;19(35):5787–5797. DOI: 10.3748/wjg.v19.i35.5787Neumann H., Mönkemüller K, Kandulski A, Malfertheiner P. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett’s esophagus. Dig. Dis. 2008;26(3):243–247. DOI: 10.1159/000121354Neumann H., Mönkemüller K, Kandulski A, Malfertheiner P. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett’s esophagus. Dig. Dis. 2008;26(3):243–247. DOI: 10.1159/000121354Noh Y.W., Jung H.-K., Kim S.-E., Jung S.-A. Оverlap of erosive and non-erosive refl ux diseases with functional gastrointestinal disorders according to Rome III criteria. J. Neurogastroenterol. Motil. 2010;16(2):148-156. DOI: 10.5056/jnm.2010.16.2.148Noh Y.W., Jung H.-K., Kim S.-E., Jung S.-A. Оverlap of erosive and non-erosive refl ux diseases with functional gastrointestinal disorders according to Rome III criteria. J. Neurogastroenterol. Motil. 2010;16(2):148-156. DOI: 10.5056/jnm.2010.16.2.148Nam S.Y., Ryu K.H., Park B.J. Irritable bowel syndrome is associa ted with gastroesophageal refl ux symptom but not erosive esophagitis. J. Neurogastroenterol. Motil. 2013;19(4):521–531. DOI: 10.5056/jnm.2013.19.4.521Nam S.Y., Ryu K.H., Park B.J. Irritable bowel syndrome is associa ted with gastroesophageal refl ux symptom but not erosive esophagitis. J. Neurogastroenterol. Motil. 2013;19(4):521–531. DOI: 10.5056/jnm.2013.19.4.521Nagasako C.K., Garcia Montes C., Silva Lorena S.L., Mesquita M.A. Irritable bowel syndrome subtypes: clinical and psychological features, body mass index and comorbidities. Rev. Esp. Enferm. Dig. 2016;108 (2):59–64. DOI: 10.17235/reed.2015.3979/2015Nagasako C.K., Garcia Montes C., Silva Lorena S.L., Mesquita M.A. Irritable bowel syndrome subtypes: clinical and psychological features, body mass index and comorbidities. Rev. Esp. Enferm. Dig. 2016;108 (2):59–64. DOI: 10.17235/reed.2015.3979/2015El-Salhy M., Gilja O.D., Hatlebakk J.G. Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Mol. Med. Rep. 2019;20(1):787–794. DOI: 10.3892/mmr.2019.10284El-Salhy M., Gilja O.D., Hatlebakk J.G. Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Mol. Med. Rep. 2019;20(1):787–794. DOI: 10.3892/mmr.2019.10284Lee K.J., Kwon H.C., Cheong J.Y., Cho S.W. Demographic, clinical, and psychological characteristics of the heartburn groups classifi ed using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal refl ux disease group. Digestion. 2009;79(3):131–136. DOI: 10.1159/000209848Lee K.J., Kwon H.C., Cheong J.Y., Cho S.W. Demographic, clinical, and psychological characteristics of the heartburn groups classifi ed using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal refl ux disease group. Digestion. 2009;79(3):131–136. DOI: 10.1159/000209848Martinucci I., de Bortoli N., Di Fluri G., Mismas V., Gambaccini D,. Leonardi G,. Bellini M., Marchi S.P. Diagnosis of NERD in a population of patients with and without IBS: a pH-MII study. Digestive and Liver Disease. 2011;43(3):168.Martinucci I., de Bortoli N., Di Fluri G., Mismas V., Gambaccini D,. Leonardi G,. Bellini M., Marchi S.P. Diagnosis of NERD in a population of patients with and without IBS: a pH-MII study. Digestive and Liver Disease. 2011;43(3):168.Fujiwara Y., Kubo M., Kohata Y., Machida H., Okazaki H., Yamagami H. et al. Cigarette smoking and its association with overlapping gastroesophageal refl ux disease, functional dyspepsia, or irritable bowel syndrome. Intern. Med. 2011;50(21):2443–2447. DOI: 10.2169/internalmedicine.50.6012Fujiwara Y., Kubo M., Kohata Y., Machida H., Okazaki H., Yamagami H. et al. Cigarette smoking and its association with overlapping gastroesophageal refl ux disease, functional dyspepsia, or irritable bowel syndrome. Intern. Med. 2011;50(21):2443–2447. DOI: 10.2169/internalmedicine.50.6012Lee Y.J., Park K.S. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World J. Gastroenterol. 2014;20(10):2456–69. DOI: 10.3748/wjg.v20.i10.2456Lee Y.J., Park K.S. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World J. Gastroenterol. 2014;20(10):2456–69. DOI: 10.3748/wjg.v20.i10.2456DuPont A.W., Jiang Z.-D., Harold S.A., Snyder N., Galler G.W. Garcia Torres F., DuPont H.L. Motility abnormalities in irritable bowel syndrome. Digestion. 2014;89(2):119–23. DOI: 10.1159/000356314DuPont A.W., Jiang Z.-D., Harold S.A., Snyder N., Galler G.W. Garcia Torres F., DuPont H.L. Motility abnormalities in irritable bowel syndrome. Digestion. 2014;89(2):119–23. DOI: 10.1159/000356314Simren M., Törbblom H., Palsson O.S., Van Tilburg V.A.L., Van Oudenhove L., Tack J. Whitehead W.E. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent fi ndings from fi ve diff erent patients. Gut. 2018;67(2):255– 262. DOI: 10.1136/gutjnl-2016-312361Simren M., Törbblom H., Palsson O.S., Van Tilburg V.A.L., Van Oudenhove L., Tack J. Whitehead W.E. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent fi ndings from fi ve diff erent patients. Gut. 2018;67(2):255– 262. DOI: 10.1136/gutjnl-2016-312361Kanazawa M., Hongo M., Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. J. Gastroenterol. Hepatol. 2011;26(3):119–21. DOI: 10.1111/j.1440-1746.2011.06640.xKanazawa M., Hongo M., Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. J. Gastroenterol. Hepatol. 2011;26(3):119–21. DOI: 10.1111/j.1440-1746.2011.06640.xDeiteren A., De Wit A., Van der Linden L., De Man J.G., Pelckmans P.A., De Winter B.Y. Irritable bowel syndrome and visceral hypersensitivity : risk factors and pathophysiological mechanisms. Acta Gastroenterol. Belg. 2016;79(1):29–38Deiteren A., De Wit A., Van der Linden L., De Man J.G., Pelckmans P.A., De Winter B.Y. Irritable bowel syndrome and visceral hypersensitivity : risk factors and pathophysiological mechanisms. Acta Gastroenterol. Belg. 2016;79(1):29–38Knowles C.H., Aziz Q. Visceral hypersensitivity in non-erosive refl ux disease. Gut. 2008;57(5):674–683. DOI: 10.1136/gut.2007.127886Knowles C.H., Aziz Q. Visceral hypersensitivity in non-erosive refl ux disease. Gut. 2008;57(5):674–683. DOI: 10.1136/gut.2007.127886Katzka D.A., Pandolfi no D.A., Kahrilas P.J. Phenotypes of gastroesophageal refl ux disease: where Rome, Lyon and Montreal meet. Clin. Gastroenterol. Hepatol. 2020;18(4):767–776. DOI: 10.1016/j.cgh.2019.07.015Katzka D.A., Pandolfi no D.A., Kahrilas P.J. Phenotypes of gastroesophageal refl ux disease: where Rome, Lyon and Montreal meet. Clin. Gastroenterol. Hepatol. 2020;18(4):767–776. DOI: 10.1016/j.cgh.2019.07.015Rubenstein J.H., Nojkov B., Korsnes S., Adlis S.A., Shaw M.J., Weinman B. et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2007;26:443–452. DOI: 10.1111/j.1365- 2036.2007.03393.xRubenstein J.H., Nojkov B., Korsnes S., Adlis S.A., Shaw M.J., Weinman B. et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2007;26:443–452. DOI: 10.1111/j.1365- 2036.2007.03393.xHsu C.S., Liu T.T., Wen S.H., Wang C.C., Yi C.H., Chen J.H. et al. Clinical, metabolic, and psychological characteristics in patients with gastroesophageal refl ux disease overlap with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2015;27(5):516–522. DOI: 10.1097/MEG.0000000000000334Hsu C.S., Liu T.T., Wen S.H., Wang C.C., Yi C.H., Chen J.H. et al. Clinical, metabolic, and psychological characteristics in patients with gastroesophageal refl ux disease overlap with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2015;27(5):516–522. DOI: 10.1097/MEG.0000000000000334Lei W.Y., Chang W.C., Wen S.H., Wong M.W., Hung J.S., Yi C.H. et al. Impact of concomitant dyspepsia and irritable bowel syndrome on symptom burden in patients with gastroesophageal refl ux disease. J. Formos. Med. Assoc. 2019;118(4):797–806. DOI: 10.1016/j.jfma.2018.12.002Lei W.Y., Chang W.C., Wen S.H., Wong M.W., Hung J.S., Yi C.H. et al. Impact of concomitant dyspepsia and irritable bowel syndrome on symptom burden in patients with gastroesophageal refl ux disease. J. Formos. Med. Assoc. 2019;118(4):797–806. DOI: 10.1016/j.jfma.2018.12.002Funaki Y., Kaneko H., Rawamura Y., Yoshimine T., Tamura Y., Izawa Sh. et al. Impact of comorbid irritable bowel syndrome on reatment outcome in non-erosive refl ux disease on long-term proton pump inhibitor in Japan. Digestion. 2017;96(1):39–45. DOI: 10.1159/000477801Funaki Y., Kaneko H., Rawamura Y., Yoshimine T., Tamura Y., Izawa Sh. et al. Impact of comorbid irritable bowel syndrome on reatment outcome in non-erosive refl ux disease on long-term proton pump inhibitor in Japan. Digestion. 2017;96(1):39–45. DOI: 10.1159/000477801Lee S.Y., Lee K.J., Kim S.J., Sung W.H. Prevalence and risk factors for overlaps between gastroesophageal refl ux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion. 2009;79(3):196–201. DOI: 10.1159/000211715Lee S.Y., Lee K.J., Kim S.J., Sung W.H. Prevalence and risk factors for overlaps between gastroesophageal refl ux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion. 2009;79(3):196–201. DOI: 10.1159/000211715De Vries D.R., Van Herwaarden M.A., Baron A., Smout A.J.P.M., Samsom M. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal refl ux disease. Scand. J. Gastroenterol. 2007;42(8):951–956. DOI: 10.1080/00365520701204204De Vries D.R., Van Herwaarden M.A., Baron A., Smout A.J.P.M., Samsom M. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal refl ux disease. Scand. J. Gastroenterol. 2007;42(8):951–956. DOI: 10.1080/00365520701204204Lacy B., Ayyagari R., Guerin A, Lopez A., Shi S., Luo M. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap. Adv. Gastroenterol. 2019;12:1756284818818326. DOI: 10.1177/1756284818818326Lacy B., Ayyagari R., Guerin A, Lopez A., Shi S., Luo M. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap. Adv. Gastroenterol. 2019;12:1756284818818326. DOI: 10.1177/1756284818818326Lee S.W., Chang C.S., Lien H.C., Peng Y.C., Wu C.Y., Yeh H.Z. Impact of overlapping functional gastrointestinal disorders on the presentation and quality of life in patients with erosive esophagitis and nonerosive refl ux disease. Med. Princ. Pract. 2015;24(5):491–495. DOI: 10.1159/000431370Lee S.W., Chang C.S., Lien H.C., Peng Y.C., Wu C.Y., Yeh H.Z. Impact of overlapping functional gastrointestinal disorders on the presentation and quality of life in patients with erosive esophagitis and nonerosive refl ux disease. Med. Princ. Pract. 2015;24(5):491–495. DOI: 10.1159/000431370Zerbib F., Belhocine K., Simon M., Cardepont M., Mion F., Bruley des Varannes S., Galmiche J.-P. Clinical, but not oesophageal pH-impedance, profi les predict response to proton pump inhibitors in gastro-oesophageal refl ux disease. Gut. 2012;61(4):501–506. DOI: 10.1136/gutjnl-2011-300798Zerbib F., Belhocine K., Simon M., Cardepont M., Mion F., Bruley des Varannes S., Galmiche J.-P. Clinical, but not oesophageal pH-impedance, profi les predict response to proton pump inhibitors in gastro-oesophageal refl ux disease. Gut. 2012;61(4):501–506. DOI: 10.1136/gutjnl-2011-300798Garros A., Mion F., Marjoux S., Damon H., Roman S. Factors associated with nonresponse to proton pump inhibitors therapy in patients referred for esophageal pH-impedance monitoring. Dis. Esophagus. 2016;29(7):787–793. DOI: 10.1111/dote.12374Garros A., Mion F., Marjoux S., Damon H., Roman S. Factors associated with nonresponse to proton pump inhibitors therapy in patients referred for esophageal pH-impedance monitoring. Dis. Esophagus. 2016;29(7):787–793. DOI: 10.1111/dote.12374Wu J.C., Lai L.H., Chow D.K., Wong G.L., Sung J.J., Chan F.K. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal refl ux disease. Neurogastroenterol. Motil. 2011;23(2):155–160.e31. DOI: 10.1111/j.1365-2982.2010.01627.xWu J.C., Lai L.H., Chow D.K., Wong G.L., Sung J.J., Chan F.K. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal refl ux disease. Neurogastroenterol. Motil. 2011;23(2):155–160.e31. DOI: 10.1111/j.1365-2982.2010.01627.xGuillemot F., Ducrotté P., Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal refl ux disease in general practice. Gastroenterol. Clin. Biol. 2005;29(3):243–246. DOI: 10.1016/s0399-8320(05)80756-0Guillemot F., Ducrotté P., Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal refl ux disease in general practice. Gastroenterol. Clin. Biol. 2005;29(3):243–246. DOI: 10.1016/s0399-8320(05)80756-0Mönnikes H., Schwan T., van Rensburg C., Straszak A., Theek C., Sander P., Lühmann P. Randomized clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suff ering from an overlap with erosive gastro-oesophageal refl ux disease. Aliment. Pharmacol. Ther. 2012;35(11):1279–1289. DOI: 10.1111/j.1365-2036.2012.05085.xMönnikes H., Schwan T., van Rensburg C., Straszak A., Theek C., Sander P., Lühmann P. Randomized clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suff ering from an overlap with erosive gastro-oesophageal refl ux disease. Aliment. Pharmacol. Ther. 2012;35(11):1279–1289. DOI: 10.1111/j.1365-2036.2012.05085.xRaftopoulos Y., Papasavas P., Landreneau R., Hayetian F., Santucci T., Gagne D. et al. Clinical outcome of laparoscopic antirefl ux surgery for patients with irritable bowel syndrome. Surg. Endosc. 2004;18(4):655–659. DOI: 10.1007/s00464-003-8162-5Raftopoulos Y., Papasavas P., Landreneau R., Hayetian F., Santucci T., Gagne D. et al. Clinical outcome of laparoscopic antirefl ux surgery for patients with irritable bowel syndrome. Surg. Endosc. 2004;18(4):655–659. DOI: 10.1007/s00464-003-8162-5Gasiorowska A., Poh C.H., Fass R. Gastroesophageal refl ux disease (GERD) and irritable bowel syndrome (IBS) — is it one disease or an overlap of two disorders? Dig. Dis. Sci. 2009;54(9):1829–1834. DOI: 10.1007/s10620-008-0594-2Gasiorowska A., Poh C.H., Fass R. Gastroesophageal refl ux disease (GERD) and irritable bowel syndrome (IBS) — is it one disease or an overlap of two disorders? Dig. Dis. Sci. 2009;54(9):1829–1834. DOI: 10.1007/s10620-008-0594-2De Bortoli N., Tolone S., Frazzoni M., Martinucci I., Sgherri G., Albano E. et al. Gastroesophageal refl ux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann. Gastroenterol. 2018;31(6):639–648. DOI: 10.20524/aog.2018.0314De Bortoli N., Tolone S., Frazzoni M., Martinucci I., Sgherri G., Albano E. et al. Gastroesophageal refl ux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann. Gastroenterol. 2018;31(6):639–648. DOI: 10.20524/aog.2018.0314Vaezi M.F., Yang Y.-X., Howden C.W. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48. Epub 2017 May 19. DOI: 10.1053/j.gastro.2017.04.047Vaezi M.F., Yang Y.-X., Howden C.W. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48. Epub 2017 May 19. DOI: 10.1053/j.gastro.2017.04.047

The authors declare that there are no conflicts of interest present.